BioPharmX announces BPX-01 reduces P. acnes by more than 90%

Final results of a phase 2A safety study of BPX-01 showed that the topical gel formulation of minocycline reduced facial P. acnes by 91% after 4 weeks, according to BioPharmX Corp.

There was a significant reduction in P. acnes at 4 weeks in BPX-01 when compared with baseline as well as compared with the control cohort, according to a press release. There were no adverse cutaneous effects reported, and no minocycline detected in the plasma.

The study randomized patients to once daily treatment of 10 mg BPX-01 minocycline topical gel or vehicle (control), according to the release. There was 100% patient satisfaction in usability and tolerability, according to an exit survey.

The reduction of P. acnes in the study was similar to that reported 1996 study of oral minocycline to treat P. acnes, according to the release. While oral minocycline is the most commonly prescribed treatment of P. acnes, it enters the bloodstream and can cause side effects, according to the release.

“This analysis of our final results suggest that BPX-01 can be effective in the reduction of P. acnes, but at a much lower, safer dose than is common with oral minocycline, the standard of care,” Anja Krammer, president of BioPharmX, stated in the release.

“The dermatology community is excited about the promise of BPX-01,” Hilary Baldwin, MD, director of the Acne Research and Treatment Center in Morristown, New Jersey, and co-chair of the BioPharmX Therapeutic Dermatology Medical Advisory Board, stated in the release. “We would love to have an effective topical treatment that fights P. acnes without exposing patients to the risk of systemic antibiotics.”

BioPharmX expects to begin a phase 2b study of BPX-01, according to the release.

Reference: www.biopharmx.com